Synapticure aims to provide neurodegenerative patients, starting with ALS, access to the best care while fueling the advancement of personalized treatments for every type of ALS. We do so by providing end-to-end clinical care using our telemedicine platform to guide patients through their entire care journey. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading ALS clinicians, biotech executives and telemedicine executives to bring the ALS care and treatment experience into the 21st century, and is backed by the leading Venture funds and Angel investors in the remote health and life sciences space.
Jason Langheier, MD, MPH is CEO & Founder of Foodsmart (Zipongo), the leader in Telenutrition, Director for the Partnership for a Healthier America & Co-Chair of Synapticure. Dr. Langheier was Co-Founder & CTO of Proventys (now US Oncology/ McKesson) that developed FDA-regulated and NIH-funded personalized cancer decision support. He studied medicine, biostatistics & clinical research at DukeMed, Harvard & UCSF respectively, and conducted neuroscience research at Duke, Cambridge, NIH & Williams.
Brian Wallach is an attorney and ALS patient. In the aftermath of his diagnosis in November 2017, he and his wife founded I AM ALS, a patient-led, patient-centric movement to lead the fight for a cure to the disease. Wallach is also an associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP. From 2014 to 2018, he served as an assistant United States attorney in the Northern District of Illinois. From 2011 to 2013, he was senior vetting counsel in the Obama White House.
Founder, SynaptiCure Inc. and eternal optimist. Recovering Bain consultant and avid baseball fan.